Zobrazeno 1 - 4
of 4
pro vyhledávání: '"11"'
Autor:
Richa Gupta, Joseph N. Contessa, Adebowale J. Adeniran, Hailey Wyatt, Kurt A. Schalper, Benjamin Y. Lu, Nicole Gianino, Adam Aguirre-Ducler, Sarah B. Goldberg, Lucia B. Jilaveanu, Veronica Chiang, Matthew Ribeiro, Harriet M. Kluger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Despite unique genetic alterations within brain metastases (BrMs) and an immunologically distinct surrounding microenvironment, the composition and functional properties of tumor-infiltrating lymphocytes within BrM remain largely unexplored. In parti
Autor:
Yukio Kageyama, Minato Yokoyama, Soichiro Yoshida, Kazutaka Saito, Junichiro Ishioka, Yoh Matsuoka, Shohei Fukuda, Yasuhisa Fujii, Yosuke Yasuda, Toshiki Kijima
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
BackgroundThe dynamic change in C-reactive protein (CRP) levels, CRP kinetics, is a prognostic factor for metastatic renal cell carcinoma (mRCC) in the tyrosine kinase inhibitor era. We investigated the impact of early CRP kinetics on the efficacy of
Autor:
Louis Boon, Isaure Vanmeerbeek, Valentina Chiappa, Tom Bourne, Thaïs Baert, Caroline Van Holsbeke, Ignace Vergote, Patrizia Agostinis, Jenny Sprooten, Abhishek D. Garg, Dirk Timmerman, Chiara Landolfo, Ann Vankerckhoven, Raquel S Laureano, Yani Berckmans, Wouter Froyman, Antonia Carla Testa, Sabine Tejpar, Dominique Schols, Daniela Fischerova, Daniel M Borras, Roxanne Wouters, An Coosemans
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundTumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing. However, current approaches for immunobiomarkers’
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea56e11e01d2ea074d0542dde941db6
http://hdl.handle.net/10807/199628
http://hdl.handle.net/10807/199628
Autor:
Limor Cohen, Cloud P. Paweletz, Biagio Ricciuti, Anika E. Adeni, David R. Walt, Julianna Supplee, Reiko Nishihara, Pasi A. Jänne, Padric M. Garden, Mariano Severgnini, Alissa Keegan, Mark M. Awad
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundBlood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB) response are lacking. We hypothesized that changes in systemic cytokine levels with the initial doses of programmed cell death protein 1 (PD-1) pathway inhibitors w